RHOA and neoplasm: Thereby, the peptides trigger a conformational reactivation of DLC1, from a “closed” towards an “open” state (Fig. 6E), allowing recruitment and interaction with potent tumour suppressors like PTEN, culminating in decreased RHOA activation, tumour cell growth and migration in vitro, proposing DLC1 as a druggable target.